Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Imatinib revolutionized chronic myeloid leukemia (CML) treatment, marking a success in targeted cancer therapy.
• Leukemic stem cells (LSCs) resist tyrosine kinase inhibitors (TKIs), causing disease persistence and relapse after treatment cessation.
• Autophagy, a cellular recycling process, protects CML cells from TKI-induced stress and supports survival in harsh microenvironments.

Purpose of the Study:

• To review the biology of CML and the development of TKIs targeting the BCR-ABL molecular driver.
• To explore the role of autophagy as a survival mechanism in CML.
• To evaluate the potential of inhibiting autophagy as a combination strategy to eradicate CML stem cells and achieve a cure.

Main Methods:

• Literature review of CML biology, TKI development, and autophagy.
• Analysis of molecular mechanisms underlying CML pathogenesis and TKI resistance.
• Discussion of autophagy's role in cancer cell survival and its inhibition as a therapeutic strategy.

Main Results:

• TKIs targeting BCR-ABL have significantly improved CML outcomes but do not eliminate LSCs.
• Autophagy acts as a crucial survival pathway for CML cells under TKI treatment.
• Inhibition of autophagy presents a promising strategy for combination therapy to target persistent CML stem cells.

Conclusions:

• Targeted therapy has transformed CML treatment, but LSC persistence remains a challenge.
• Autophagy inhibition is an emerging therapeutic avenue for combination treatment in CML.
• Combining TKIs with autophagy inhibitors holds potential for achieving a curative option in CML.